ADMA Biologics Inc (ADMA) vs Trevi Therapeutics, Inc. (TRVI)

ADMA Biologics Inc and Trevi Therapeutics, Inc. are both Biotechnology companies. ADMA Biologics Inc and Trevi Therapeutics, Inc. are of similar size ($2.1B and $2.1B). Trevi Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; ADMA Biologics Inc trades at 13.0×. ADMA Biologics Inc has the higher net margin (33.0% vs 0.00%) and the higher return on invested capital (29.8% vs −1,412.1%). Across the 14 metrics below, ADMA Biologics Inc leads on 11 and Trevi Therapeutics, Inc. on 3.

Valuation

Metric ADMA TRVI Biotechnology median
P/E 13.03 n/m 7.88
P/S 4.18 n/m 11.47
P/B 5.24 7.02 2.52
Price to free cash flow 18.42 n/m 21.16
EV/EBITDA 9.47 n/m 0.74
EV/Sales 4.30 n/m 10.73
Earnings yield 7.68% (2.36%) (28.84%)
Free cash flow yield 5.43% (2.34%) (23.03%)

Profitability

Metric ADMA TRVI Biotechnology median
Gross margin 64.71% 0.00% 65.16%
Operating margin 43.82% 0.00% 0.00%
Net margin 32.98% 0.00% 0.00%
Free cash flow margin 22.69% 0.00% 0.00%
Return on equity 41.90% (19.66%) (57.72%)
Return on assets 27.19% (18.97%) (49.22%)
Return on invested capital 29.78% (1,412.11%) 0.00%

Growth

Metric ADMA TRVI Biotechnology median
Revenue growth (TTM) 8.04% — 5.64%
EPS growth (last fiscal year) (25.93%) 31.91% —
Revenue growth, 5-year CAGR 64.60% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADMA TRVI Biotechnology median
Debt to equity 0.49 0.00 0.00
Current ratio 6.97 37.28 4.73
Net debt to EBITDA (0.06) 3.83 0.96

Dividend

Metric ADMA TRVI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ADMA TRVI Biotechnology median
Market cap 2.13b 2.09b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack